Mid Caps
All Mid Caps coverage
UNFI ends fiscal 2026 with adjusted EBITDA up 27% as net sales fall 2%
The grocery wholesaler beat consensus on fourth-quarter adjusted earnings but came in light on revenue, then set a fiscal 2027 sales range below the analyst estimate while approving a new $200m buyback.
American Healthcare REIT Buys Eight East Coast Senior Housing Communities for About $696 Million
The 867-unit portfolio was built between 2020 and 2022 and will be run almost entirely by LCB Senior Living. The purchase pushes the REIT's disclosed 2026 investment total past $2 billion.
Scholar Rock Wins FDA Fast Track and Orphan Drug Status for Apitegromab in FSHD as Phase 2 Dosing Begins
The designations open a second indication for the myostatin inhibitor four weeks before its Sept. 30 FDA action date in spinal muscular atrophy. The company had $492.1 million of cash at June 30 and is not yet profitable.
Protagonist Banks $275 Million on FDA Approval of MIMRYLO, Its Second US Clearance of 2026
The peptide developer opted out of co-funding rusfertide in April, handing Takeda the commercial burden in exchange for a $200 million fee plus a $75 million approval milestone. It keeps tiered royalties of 14% to 29% on worldwide sales of the first hepcidin mimetic cleared for polycythemia vera.
Solstice and Element Solutions Call Off $14.5 Billion Merger as Solstice Authorizes $500 Million Buyback
The two advanced-materials companies mutually terminated the cash-and-stock combination announced in July, with no fees payable by either side despite reciprocal break fees written into the agreement. Solstice cited conversations with shareholders, authorized a new $500 million buyback and reaffirmed its 2026 outlook.
Box Raises Fiscal 2027 Revenue Outlook to About $1.29 Billion After Billings Climb 17%
Second-quarter revenue reached $321.1 million and net retention improved to 106%. The company bought back 2.6 million shares for roughly $66 million in the quarter and has $378 million left on its authorization.
OSI Systems posts record cash flow and a record backlog, then loses more than a tenth of its value. The problem was the top line and the fiscal 2027 outlook, not the earnings line.
The airport-scanner and optoelectronics maker reported fiscal fourth-quarter revenue of $484.1 million, down 4% year over year and about 8.5% short of the $529 million analysts expected, according to StockStory. Non-GAAP earnings per share of $3.78 were essentially in line, and fiscal 2027 non-GAAP EPS guidance of $11.13 to $11.49 brackets a midpoint slightly below consensus.
Mercury Systems Books $660 Million in Fiscal Q4 but Margins Slip; Shares Close Lower
The defense electronics supplier reported quarterly revenue of $289.8 million and a 2.28 book-to-bill, yet GAAP net income fell to $0.8 million from $16.4 million and adjusted EBITDA margin narrowed to 16.7% from 18.8%. Shares closed Wednesday at $101.25, down 3.6%.
Mercury Systems Closes Fiscal 2026 on Tuesday, and Consensus Already Assumes the Quarter Got Spent Early
The defense-electronics maker reports fourth-quarter and full-year results after Tuesday's close. Analysts model adjusted earnings and revenue below last year's June quarter — a setup that traces back to management's own disclosure that roughly $25 million of revenue primarily planned for the fourth quarter was generated in the third instead.
Ultragenyx Faces Two Gene-Therapy Decision Dates 27 Days Apart, One a Re-Run of a Manufacturing Rejection
The FDA has set target action dates of August 23 and September 19, 2026 for two of Ultragenyx's AAV gene therapies. The second is a resubmission after a July 2025 Complete Response Letter that the company says cited chemistry, manufacturing and controls issues only, with no review issues flagged on the clinical data package. Ultragenyx reported $436 million in cash, equivalents and marketable securities at June 30, 2026, against $214 million of quarterly revenue. Both goal dates fall on a weekend.
Applied Optoelectronics Gained 15% on Friday With No Identified Company Catalyst. The Filings Explain What the Tape Did Not.
AAOI closed at $150.28 in a session that trackers could not pin to a same-day catalyst, so we went back to the quarter and the 10-Q: record revenue, a widening GAAP loss, three customers supplying nearly all of it, and a $12.7 billion market value that no longer belongs to a small cap.
X-energy jumped 11.7% on a quarter where operating expenses ran three times the top line
The nuclear developer's first-half revenue and grant income rose 132% to $98 million while operating expenses reached $274 million. With $1.9 billion of liquidity and no reactors in commercial operation, X-energy is a mid cap priced on milestones rather than earnings — and it is not the only one heading into a decisive week.
BETA Technologies falls on a wider quarterly loss even as revenue beats its own guidance
The Vermont electric-aircraft maker reported second-quarter revenue of $14.7 million, well above the $8 million to $11 million it had guided to, but an adjusted loss of $0.64 a share against a $0.46 consensus. The stock fell on a day the broad market rose.